Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $5,270,902.00 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 115,844 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the transaction, the director directly owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. This trade represents a 4.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Wednesday, May 27th, Orbimed Advisors Llc sold 101 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total transaction of $4,493.49.
• On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58.
• On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.58, for a total transaction of $2,664,412.86.
• On Thursday, May 7th, Orbimed Advisors Llc sold 48,546 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.61, for a total transaction of $2,165,637.06.
• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.52, for a total transaction of $131,244.96.
• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.68, for a total value of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The shares were sold at an average price of $45.34, for a total value of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total value of $2,128,201.14.

Sionna Therapeutics Price Performance

SION opened at $43.99 on Friday. Sionna Therapeutics, Inc. has a 12 month low of $16.38 and a 12 month high of $48.44. The stock has a market cap of $1.99 billion, a P/E ratio of -22.79 and a beta of 1.33. The stock’s 50 day moving average price is $39.85 and its 200 day moving average price is $39.53.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Equities analysts anticipate that Sionna Therapeutics, Inc. will post -2.57 EPS for the current year.

Institutional Trading of Sionna Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SION. Russell Investments Group Ltd. acquired a new stake in shares of Sionna Therapeutics in the third quarter valued at $30,000. BNP Paribas Financial Markets acquired a new position in Sionna Therapeutics during the second quarter worth about $31,000. GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics in the fourth quarter worth about $36,000. Balyasny Asset Management L.P. bought a new stake in Sionna Therapeutics in the fourth quarter worth about $58,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Sionna Therapeutics in the 4th quarter valued at about $89,000.

Analysts Set New Price Targets

SION has been the topic of a number of recent analyst reports. Wedbush began coverage on shares of Sionna Therapeutics in a research note on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price objective on the stock. BTIG Research reiterated a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research report on Wednesday, May 13th. Wall Street Zen cut shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Freedom Capital downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.22.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.